{"DataElement":{"publicId":"3919427","version":"1","preferredName":"Contraception Agreement Yes No N/A Indicator","preferredDefinition":"The yes/no/na indicator relating to the patient's agreement to use effective contraception during protocol treatment.","longName":"CONTRACEPTION_AGR_INDI","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014053","version":"1","preferredName":"Contraception Agreement","preferredDefinition":"the patient's agreement to use effective contraception during protocol treatment.","longName":"CONTRACEPTION_AGR","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2725194","version":"1","preferredName":"Contraception","preferredDefinition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","longName":"C37932","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contraception","conceptCode":"C37932","definition":"The prevention of conception or impregnation by the use of devices or drugs or surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"448E87D9-8E4A-47E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-25","modifiedBy":"ONEDATA","dateModified":"2008-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2520617","version":"1","preferredName":"Agreement","preferredDefinition":"1. The act of agreeing. 2. Harmony of opinion; accord. (from American Heritage Dictionary)","longName":"C25369","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agreement","conceptCode":"C25369","definition":"The act of agreeing to a plan, protocol, or arrangement. Also used to describe a harmony of opinion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DFE6E80-0641-12A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-21","endDate":null,"createdBy":"AYANLOWA","dateCreated":"2006-09-21","modifiedBy":"ONEDATA","dateModified":"2006-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008542","version":"1","preferredName":"Reproduction","preferredDefinition":"the patient's ability to conceive or nurse offspring and/or their current reproductive status.","longName":"REPRODUCTION","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227DAE6-EC15-4A7D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B318870A-C908-3702-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3919425","version":"1","preferredName":"Yes No N/A Indicator","preferredDefinition":"The value domain to indicate a question with permissible values of yes/no/na.","longName":"Indi","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"N/A","valueDescription":"N/A","ValueMeaning":{"publicId":"2561784","version":"1","preferredName":"N/A","longName":"2561784","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE65-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-09","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CA7C7F-FE24-3690-E040-BB89AD43404F","beginDate":"2005-04-11","endDate":null,"createdBy":"ABRAHAML","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CA7C7F-FE2E-3690-E040-BB89AD43404F","beginDate":"2005-04-11","endDate":null,"createdBy":"ABRAHAML","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8CA7C7F-FE38-3690-E040-BB89AD43404F","beginDate":"2005-04-11","endDate":null,"createdBy":"ABRAHAML","dateCreated":"2013-10-15","modifiedBy":"ONEDATA","dateModified":"2013-10-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C7F-FE0F-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ABRAHAML","dateCreated":"2013-10-15","modifiedBy":"KUMMEROA","dateModified":"2022-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3335728","version":"1","longName":"Protocols","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4264871","version":"1","longName":"ABTC 1302","context":"ABTC"}]},{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]},{"publicId":"5999742","version":"1","longName":"CRF CDEs","context":"CITN","ClassificationSchemeItems":[{"publicId":"5999747","version":"1","longName":"Eligibility CDEs","context":"CITN"}]}],"AlternateNames":[{"name":"ABTC","type":"USED_BY","context":"ABTC"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"CONTRACEPTION_AGR_INDI","type":"USED_BY","context":"NRG"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"CONTRACEPTION_AGR_INDI","type":"USED_BY","context":"CITN"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"CONTRACEPTION_AGR_INDI","type":"USED_BY","context":"CCTG"},{"name":"IE_IEORRES_CONTRACEPTION","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Women of childbearing potenti","type":"Preferred Question Text","description":"Women of childbearing potential and men must agree to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time the consent is signed, for the duration of study participation, and 4 months after discontinuation of protocol therapy.  If not a woman of childbearing potential (check N/A).","url":null,"context":"CTEP"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a male participant did they agree to practice adequate contraception throughout the study?","url":null,"context":"NRG"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Women of childbearing potential and men must agree to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) before study entry, for the duration of study participation, and 4 months after discontinuation of CDX-1401 or CDX-301 therapy. If not a woman of childbearing potential, please check N/A","url":null,"context":"CTEP"},{"name":"ABTC Question Text","type":"Alternate Question Text","description":"Did the male patient agree to use adequate contraception prior to the study, for the duration of the study participation, and for 4 months after completion of lapatinib administration?","url":null,"context":"ABTC"},{"name":"Theradex question","type":"Alternate Question Text","description":"Does male patient of fathering potential, agree to use an adequate method of contraception throughout the study and for up to 12 weeks after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex Question 2","type":"Alternate Question Text","description":"Does female patient of childbearing potential, agree to use an adequate method of contraception throughout the study and for up to 12 weeks after the last dose of study drug?","url":null,"context":"Theradex"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Female patients of childbearing potential and male patients should be willing to use 2 methods of contraception (birth control or be surgically sterile, or abstain from heterosexual activity) starting with the screening visit, for the duration of study participation, and through 120 days beyond last dose of MK-3475 administration. If not a woman of childbearing potential, please check N/A","url":null,"context":"CTEP"},{"name":"CRF Text 5","type":"Alternate Question Text","description":"Female patients of childbearing potential and male patients should be willing to use 2 methods of contraception (birth control or be surgically sterile, or abstain from heterosexual activity) for the course of the study through 120 days after the last dose of study medication.  If not a woman of childbearing potential, please check N/A.","url":null,"context":"CTEP"},{"name":"CITN","type":"Alternate Question Text","description":"Female patients must be surgically sterile, be post-menopausal, or must agree to use effective contraception. Women or men of reproductive potential must agree to use an effective contraceptive method during the period of therapy and for 90 days following the last dose of RO7009789. If not a woman of reproductive potential, please check N/A.","url":null,"context":"CITN"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Has female patients of childbearing potential and men receiving pembrolizumab who are sexually active with women of childbearing potential agreed to use an adequate method of contraception for the course of the study through 120 days after the last dose of pembrolizumab","url":null,"context":"NRG"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Female patient of childbearing potential agrees to and will have had effective contraception without interruption for 28 days before starting pomalidomide? (See Protocol Appendix F)","url":null,"context":"PBTC"},{"name":"CRF_text_7","type":"Alternate Question Text","description":"Is the patient unwilling to employ adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of this study treatment and for 3 months after the last dose of study therapy?","url":null,"context":"CTEP"},{"name":"EAI142 CRF","type":"Alternate Question Text","description":"If patient is a female of childbearing potential or a sexually active man, has patient indicated their agreement to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study?","url":null,"context":"ECOG-ACRIN"},{"name":"EAI142 TEXT","type":"Alternate Question Text","description":"Patient is a premenopausal woman, postmenopausal woman, or man for whom endocrine therapy (tamoxifen, aromatase inhibitor [AI], with or without ovarian suppression or fulvestrant), with or without a CDK4/6 inhibitor, is planned after FES-PET/CT is completed","url":null,"context":"ECOG-ACRIN"},{"name":"ABTC 1302","type":"Alternate Question Text","description":"Women of child bearing potential and men must agree to use 1 highly effective method of contraception and 1  additional effective (barrier) method prior to and for the duration of the study. Contraception methods must be continued for 90 days post last dose for women and 120 days post last dose for men.","url":null,"context":"ABTC"},{"name":"ABTC-1601","type":"Alternate Question Text","description":"Women of childbearing potential must agree to use highly-effective contraceptive methods for the duration of study and for 90 days after the last dose of study drug.","url":null,"context":"ABTC"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"If female,has patient agreed to use an effective contraceptive method for 4 months after last treatment dose?","url":null,"context":"COG"},{"name":"CITN-1","type":"Alternate Question Text","description":"Patient (female or male) has agreed to use an adequate method of contraception (birth control or be surgically sterile, or abstain from heterosexual activity) starting with the first dose of study therapy, for the duration of study participation, and through 120 days beyond the last dose of study medication. If not a woman of childbearing potential, please check N/A.","url":null,"context":"CITN"},{"name":"CE7","type":"Alternate Question Text","description":"Women and men of childbearing potential must have agreed to use a highly effective contraceptive method.","url":null,"context":"CCTG"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Is the patient unwilling to employ adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of this study treatment and for 4 months after the last dose of study therapy?","url":null,"context":"CTEP"},{"name":"NRG_CRF_TEXT1","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a sexually active man, have they been instructed on the use of medically acceptable forms of contraception for 180 days post treatment?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text 2","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a sexually active man, have they been instructed on the use of medically acceptable forms of contraception during treatment and for 3 months after the last dose of durvalumab?","url":null,"context":"NRG"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Does the patient agree to use adequate contraception (non-hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab/placebo and 7 months after the last dose of trastuzumab and pertuzumab?","url":null,"context":"CTEP"},{"name":"CITN Female participants of childbearing potential and male participants with partners of childbearing potential, agree to use highly effective form(s) of contraception as outlined in protocol Section 5.7","type":"Alternate Question Text","description":"Female participants of childbearing potential and male participants with partners of childbearing potential, agree to use highly effective form(s) of contraception as outlined in protocol Section 5.7","url":null,"context":"CITN"},{"name":"NRG_CRF_Text 3","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a sexually active man, have they been instructed on the use of medically acceptable forms of contraception during treatment and for 150 days after the last dose of study drug (Arm 2)?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text4","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a sexually active man, have they been instructed on the use of medically acceptable forms of contraception within 14 days from Step 1 registration","url":null,"context":"NRG"},{"name":"NRG_CRF_TEXT10","type":"Alternate Question Text","description":"If the patient is a women of childbearing potential (WOCBP) or a man who is sexually active with WOCBP, are they willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text5","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a sexually active man, have they agreed on the use of medically acceptable forms of contraception per protocol requirements?","url":null,"context":"NRG"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is female of child-bearing potential, patient will not use any hormonal means of birth control such as oral, injectable, dermal, subdermal or topical contraceptives?","url":null,"context":"Theradex"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has female patient of reproductive potential agreed to 1 method of highly effective contraceptive for the duration of study participation and for at least 28 days after the last dose of Nirogacestat?","url":null,"context":"COG"},{"name":"NRG_CRF_Text_11","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a sexually active man, have they been instructed on the use of medically acceptable forms of contraception for 150 days post treatment?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text6","type":"Alternate Question Text","description":"Willing to use highly effective contraceptives for participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) during therapy and for 14 months (females); for 11 months (males) following last dose of cisplatin","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_12","type":"Alternate Question Text","description":"Does the patient, including men with vasectomies if they are having sex with WOCBP or with a woman who is pregnant, agree to use a highly effective method of contraception while on study drug and for 6 months following the last dose of study drug","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_13","type":"Alternate Question Text","description":"Participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) unwilling to use highly effective contraceptives during and for six months after end of treatment because the treatment in this study may be significantly teratogenic.","url":null,"context":"NRG"},{"name":"NRG CRF Text 7","type":"Alternate Question Text","description":"If the participant is of childbearing potential (may become pregnant or impregnate a partner) are they unwilling to use highly effective contraceptives during therapy and for 90 days after all protocol directed therapy?","url":null,"context":"NRG"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Patients of childbearing potential must have agreed to use a highly effective contraceptive method.","url":null,"context":"CCTG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Does the patient agree to use highly effective contraception depending on the treatment arm?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text_14","type":"Alternate Question Text","description":"If the patient is a woman of childbearing potential or a sexually active man, have they been instructed on the use of medically acceptable forms of contraception during treatment and for 3 months after the last dose of treatment?","url":null,"context":"NRG"},{"name":"CCTG_02","type":"Alternate Question Text","description":"Participant of childbearing potential must have agreed to use a highly effective contraceptive method.","url":null,"context":"CCTG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C7F-FE42-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ABRAHAML","dateCreated":"2013-10-15","modifiedBy":"CLOHNES","dateModified":"2023-11-16","changeDescription":null,"administrativeNotes":"2/14/23 added AQT for NRG ticket number CADSR0002048 cjl; 12/20/22 added AQT for ticket number CADSR0001818 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}